MX2020011164A - Compuesto de formamida, método de preparación para el mismo y aplicación del mismo. - Google Patents

Compuesto de formamida, método de preparación para el mismo y aplicación del mismo.

Info

Publication number
MX2020011164A
MX2020011164A MX2020011164A MX2020011164A MX2020011164A MX 2020011164 A MX2020011164 A MX 2020011164A MX 2020011164 A MX2020011164 A MX 2020011164A MX 2020011164 A MX2020011164 A MX 2020011164A MX 2020011164 A MX2020011164 A MX 2020011164A
Authority
MX
Mexico
Prior art keywords
diseases
compound
preparation
application
method therefor
Prior art date
Application number
MX2020011164A
Other languages
English (en)
Inventor
Zhibin Li
Kun Zhang
Desi Pan
Song Shan
Qianjiao Yang
Xianping Lu
Xiaoliang Wang
Yonglian Song
Original Assignee
Shenzhen Chipscreen Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Chipscreen Biosciences Co Ltd filed Critical Shenzhen Chipscreen Biosciences Co Ltd
Publication of MX2020011164A publication Critical patent/MX2020011164A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de formamida, a un método de preparación para el mismo y a una aplicación del mismo. La estructura del compuesto se muestra en la fórmula (I) y la definición de cada variable de la fórmula es como se proporciona en la descripción. El compuesto es capaz de inhibir la actividad de la cinasa ASK1. El compuesto de la presente invención puede usarse en el tratamiento/prevención de enfermedades asociadas a la cinasa ASK1, tales como enfermedades inflamatorias, enfermedades metabólicas, enfermedades autoinmunitarias, enfermedades cardiovasculares, enfermedades neurodegenerativas, cánceres y otras enfermedades.
MX2020011164A 2018-04-28 2019-04-23 Compuesto de formamida, método de preparación para el mismo y aplicación del mismo. MX2020011164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810404758.XA CN110407806B (zh) 2018-04-28 2018-04-28 甲酰胺类化合物、其制备方法及其应用
PCT/CN2019/083829 WO2019206120A1 (zh) 2018-04-28 2019-04-23 甲酰胺类化合物、其制备方法及其应用

Publications (1)

Publication Number Publication Date
MX2020011164A true MX2020011164A (es) 2021-02-09

Family

ID=68294834

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011164A MX2020011164A (es) 2018-04-28 2019-04-23 Compuesto de formamida, método de preparación para el mismo y aplicación del mismo.

Country Status (12)

Country Link
US (1) US20210139454A1 (es)
EP (1) EP3789384A4 (es)
JP (1) JP2021519808A (es)
KR (1) KR20210005135A (es)
CN (1) CN110407806B (es)
AU (1) AU2019260217B2 (es)
BR (1) BR112020021664A2 (es)
CA (1) CA3098202A1 (es)
MX (1) MX2020011164A (es)
TW (1) TWI694824B (es)
UA (1) UA125056C2 (es)
WO (1) WO2019206120A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114470217B (zh) * 2020-11-24 2023-06-20 深圳微芯生物科技股份有限公司 预防和治疗代谢异常或炎症引起的组织损伤的药物组合物
CN114246866B (zh) * 2021-04-28 2023-09-12 深圳微芯生物科技股份有限公司 用于治疗慢性肾病的药物及其用途
CN113200924B (zh) * 2021-05-18 2022-11-01 南开大学 一种4-氨基-5-嘧啶甲酰胺类化合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027283A1 (en) 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
UY32417A (es) * 2009-02-05 2010-08-31 Takeda Pharmaceutical Compuestos de piridazinona
TWI598347B (zh) * 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011041293A1 (en) * 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
EA023040B1 (ru) * 2010-07-02 2016-04-29 Джилид Сайэнс, Инк. Ингибиторы киназ, регулирующих апоптозный сигнал
UY34573A (es) * 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
UY35212A (es) * 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
MX2016008254A (es) * 2013-12-20 2016-10-14 Gilead Sciences Inc Inhibidores de cinasa reguladora de la señal de apoptosis.
WO2018183122A1 (en) * 2017-03-27 2018-10-04 Sidecar Therapeutics, Inc. Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds
JOP20190221A1 (ar) * 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها

Also Published As

Publication number Publication date
EP3789384A1 (en) 2021-03-10
WO2019206120A1 (zh) 2019-10-31
KR20210005135A (ko) 2021-01-13
CN110407806A (zh) 2019-11-05
BR112020021664A2 (pt) 2021-01-26
AU2019260217A1 (en) 2020-11-19
CN110407806B (zh) 2021-08-17
AU2019260217B2 (en) 2021-12-09
TWI694824B (zh) 2020-06-01
CA3098202A1 (en) 2019-10-31
EP3789384A4 (en) 2021-12-01
JP2021519808A (ja) 2021-08-12
TW201946623A (zh) 2019-12-16
US20210139454A1 (en) 2021-05-13
UA125056C2 (uk) 2021-12-29

Similar Documents

Publication Publication Date Title
MX2020011164A (es) Compuesto de formamida, método de preparación para el mismo y aplicación del mismo.
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
PH12016501702A1 (en) Pyrazole amide derivative
WO2017136727A3 (en) Inhibitors of receptor-interacting protein kinase 1
MX2021002412A (es) Vesiculas derivadas de lactobacillus paracasei y uso de las mismas.
PH12020551175A1 (en) Non-fused thiophene derivatives and their uses
WO2015022545A3 (en) Stem cell microparticles and mirna
MX2020007918A (es) Derivados fusionados de tiofeno y sus usos.
MX2023004221A (es) Inhibidores de rad51.
GEP20227344B (en) Pyrimidine compound as jak kinase inhibitor
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX2019000795A (es) Composiciones de limpieza liquidas con sistema antibacteriano y metodo para su fabricacion.
MX359656B (es) Derivados de oxoquinazolinil-butanamida.
NZ730790A (en) Composition of (6s)-5-methyl tetrahydrofolic acid or salt thereof as well as preparation therefor and application thereof
WO2016176620A8 (en) Extracellular matrix compositions for the treatment of cancer or immunological diseases
WO2017035176A8 (en) Method of preventing or treating obesity with an emc10 inhibitor
MX2019012285A (es) Metodos de tratamiento de encefalopatias del desarrollo.
MX2020002852A (es) Tratamiento mejorado de dermatitis atopica con tradipitant.
GEP20237483B (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
CA3082254A1 (en) Heterocyclic compounds as kinase inhibitors
EP4292652A3 (en) Compounds for the treatment of glycogen storage disorders
PH12020550537A1 (en) Bicyclic sulfones and sulfoxides and methods of use thereof
MX2018012800A (es) Administracion de metabolitos de berberina.
GB2518776A (en) Plating of articles
WO2015161824A3 (en) Sesquiterpenoids